ImmunoGen, based in Norwood, MA, is a pioneering biotechnology company dedicated to developing innovative antibody-drug conjugates (ADCs) for the targeted treatment of cancer. With a rich history spanning 40 years, ImmunoGen's mission is to disrupt the progression of cancer and improve the quality of life for patients by delivering toxic drugs directly to cancer cells.
Driven by a commitment to advancing oncology research, ImmunoGen has made significant strides in the field, including the development of groundbreaking therapies like ELAHERE mirvetuximab soravtansine-gynx. Recently acquired by AbbVie, ImmunoGen continues to push boundaries in cancer treatment, aiming to set new standards of care and provide hope for patients facing challenging diagnoses.
Generated from the website